Long-awaited Faricimab for wet AMD and DME approved

The FDA has approved Genentech’s Vabysmo (first announced here as faricimab), the only injectable eye medicine approved simultaneously in the U.S. for wet age-related macular degeneration (AMD) and diabetic macular edema (DME). Vabysmo will be administered using flexible dosing regimens based on patient need. The medication targets and inhibits two disease pathways by neutralizing angiopoietin-2 [Read More]

Cataract Surgery Shown to Reduce Risk of Dementia

Researchers at Kaiser Permanente Washington have found strong evidence that cataract surgery can lower the risk of developing dementia for up to 10 years in senior adults. The news was reported in the December 6, 2021 issue of JAMA Internal Medicine. The Adult Changes in Thought (ACT) study of more than 5,000 senior adults showed [Read More]

Prevent Blindness Launches New Awareness Initiative to Educate Public About Geographic Atrophy

Prevent Blindness has launched its first-ever Geographic Atrophy (GA) Awareness Week from December 6-12, 2021. GA is an advanced form of dry age-related macular degeneration (commonly referred to as AMD) which leads to vision loss in the center of one’s vision. Geographic atrophy results in areas of damaged tissue causing central blind spots. It is [Read More]

FDA Approves First Biosimilar Drug for Treatment of Wet AMD

The U.S. Food and Drug Administration (FDA) has approved Byooviz (ranibizumab-nuna) as the first biosimilar to Lucentis (ranibizumab injection) for the treatment of wet AMD. Byooviz is also approved to treat macular edema and myopic choroidal neovascularization, a vision-threatening complication of myopia (nearsightedness). The drug is administered by intravitreal injection (delivered into the vitreous humor [Read More]

FDA Approves Genentech’s Susvimo, a First-of-Its-Kind Therapeutic Approach for Wet Age-Related Macular Degeneration (AMD)

Susvimo, previously called Port Delivery System with ranibizumab, is the first wet AMD treatment in 15 years to provide an alternative to standard-of-care eye injections needed as often as once a month. By continuously delivering medicine into the eye through a refillable implant, Susvimo may help people with wet AMD maintain their vision with as [Read More]